YUVIWEL approved and generating revenue, but a 20% BioMarin royalty burden tests whether achondroplasia economics support the combination therapy ambition

Ascendis Pharma is a commercial-stage company with YUVIWEL, an approved targeted therapy for achondroplasia that is now generating revenue.

YUVIWEL (navepegritide) launched into achondroplasia with BioMarin's vosoritide as the only approved rival, but a binding settlement now strips 20% of U.S. net sales and 18% in key EU markets through May 2030. The thesis resolves on whether the COACH combination data, which pushed mean annualized growth velocity to or above the 97th percentile, is sufficient to justify combination pricing and volume that offsets the royalty drag. The primary risk is structural: royalty-burdened unit economics on the lead product before the reACHin infant filing creates a durable label extension.